Nutriband partners with Brand Institute to develop name for opioid patch

ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a $95 million market cap pharmaceutical company that has seen its stock surge over 67% in the past six months, has initiated the commercial brand name development process for its lead product, an abuse-deterrent fentanyl transdermal system, according to a press release issued Friday.

The company has partnered with Brand Institute, Inc., a firm specializing in pharmaceutical brand name development that claims a 75% share of drug name approvals globally and 87% of FDA approved names in 2024. According to InvestingPro data, Nutriband maintains a healthy financial position with a current ratio of 4.78, indicating strong liquidity to fund its development initiatives.

The product, currently under the development name AVERSA™ FENTANYL, aims to be the first abuse-deterrent opioid patch designed to deter misuse and reduce accidental exposure risks. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs with high potential for misuse.

Nutriband’s AVERSA™ technology is protected by patents in 46 countries including the United States, Europe, Japan, China, and Australia.

Brand Institute’s wholly owned regulatory subsidiary, Drug Safety Institute, will provide regulatory support for the project. The subsidiary is staffed by former officials from regulatory agencies including the FDA, European Medicines Agency, and Health Canada.

The development of a distinctive brand name is considered a critical element in pharmaceutical product development to prevent medication errors that could result from confusion with similarly named drugs.

Nutriband, which is primarily engaged in developing transdermal pharmaceutical products, trades on the Nasdaq under the ticker NTRB. While the company posted impressive revenue growth of 43% in the latest quarter, InvestingPro analysis suggests the stock may be undervalued, with additional insights available to subscribers through 8 more exclusive ProTips.

In other recent news, Nutriband Inc. reported a significant 50.87% increase in revenue for the first half of 2025, totaling $1,289,884. The company also disclosed that stock options and warrants were exercised, bringing in gross proceeds of approximately $5.35 million. In addition to these financial developments, Nutriband has filed a provisional patent application to enhance the intellectual property protection of its AVERSA™ abuse deterrent transdermal technology. This move aims to improve the abuse deterrent properties of patches containing opioids and stimulants. Furthermore, the U.S. Food and Drug Administration (FDA) has granted a Type C Meeting to Nutriband for its AVERSA FENTANYL product, an abuse-deterrent fentanyl transdermal system. The meeting, set for September 18, 2025, will provide feedback on the product’s Chemistry, Manufacturing, and Controls plans. These developments indicate ongoing efforts by Nutriband to advance its product pipeline and strengthen its financial position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.